NEUMORA THERAPEUTICS, INC. — Operating Income by Fiscal Year
4 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/25b70949-bf81-4a6d-9a6b-094321e4bab4/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-241.2M | 2025-01-01 – 2025-12-31 | evidence 0001193125-26-130388 |
| FY 2024 | $-263.5M | 2024-01-01 – 2024-12-31 | evidence 0000950170-25-030401 |
| FY 2023 | $-252.1M | 2023-01-01 – 2023-12-31 | evidence 0000950170-24-027927 |
| FY 2022 | $-135.9M | 2022-01-01 – 2022-12-31 | evidence 0000950170-24-027927 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).